Unlearn.AI Ads

Read the paper on why AI announcements rarely show up in published trial results

AI that holds up at a readout starts upstream of the announcement. Our paper shows what credible AI in clinical development actually requires.AI that holds up at a readout starts upstream of the announcement. Our paper shows what credible AI in clinical development at %COMPANYNAME% actually requires.

Read the whitepaper on the alternative to Decision Debt

Decision Compounding: each program sharpening the assumptions of the next. The whitepaper makes the case in full.

Read the whitepaper that names the condition behind the symptoms

These are not separate operational problems. They are symptoms of Decision Debt, the condition behind them all. Our whitepaper names it.

See where Decision Debt accrues and how to clear it.

Scattered rationale, lost assumptions, late signals. We call it Decision Debt, and it’s inflating the cost of each trial you run.

Different delays and one root cause.

Failed programs, expensive amendments, and chronic delays trace to one upstream condition. We call it Decision Debt.

Get the whitepaper

In oncology, the more precisely you define your population, the less data you have to work with.

Read the paper on what fragmented workflows cost your clinical program

Every additional scenario means reassembling evidence, re-running analyses, realigning across functions. Our paper explains what that friction costs.

Unlearn’s expert analysis

Published trial data and real-world data were never designed to work together. That’s the bottleneck in oncology trial design.

Get the whitepaper

RWD ages. Populations narrow. The result is the same: patient-level data alone can’t characterize expected outcomes for the trials you’re designing today.

Read the paper on what that gap actually costs

Evidence in one place, assumptions in another, scenarios in a third. Clinical trial design often lives between tools. Our new paper explains what that costs.

Read the paper on what that gap actually costs

Evidence in one place, assumptions in another, scenarios in a third. Clinical trial design often lives between tools. Our new paper explains what that costs.

See the results

We predicted BREAKWATER SoC arm OS without a single BREAKWATER patient in our calibration data. Calibrated only to unselected mCRC trials. The curve is in the whitepaper.

Get the whitepaper

Your RWD search returns 5 patients. Your trial needs 200. This is the precision oncology data problem and it’s getting harder as populations narrow.

Most AI investment in pharma is in discovery

Most AI investment in pharma has gone into discovery. Clinical development, where programs actually fail, has gotten less attention. We wrote about why.

See the cost model

Evidence scattered across searches, spreadsheets, and slide decks. Every design iteration starts from scratch. Our new paper explains why that fragmentation persists — and what it costs before a single patient enrolls.

Read the paper on why most pharma AI never reaches a protocol

Pharma’s big investments in AI aren’t showing up in protocols. Our paper names why, and shows what a connected alternative looks like.%COMPANYNAME%’s big investments in AI aren’t showing up in protocols. Our paper names why, and shows what a connected alternative looks like.

Unlearn’s perspective

Oncology sponsors now commit to Phase III designs earlier, with less time to validate assumptions. The margin for error is shrinking.

Unlearn’s take

Most oncology trial amendments trace back to outcome assumptions that were wrong before the first patient enrolled.

The stats layer you can't skip

No regulator or clinical team is going to accept "we asked the LLM what the treatment effect is." We wrote about what does.

The hardest part of clinical AI is the data

Small, siloed, and heterogeneous. Different schemas, different missingness conventions, different visit windows. We wrote about how to work with it.

Read the paper on what that gap actually costs

Evidence in one place, assumptions in another, scenarios in a third. Clinical trial design often lives between tools. Our new paper explains what that costs.

AI in clinical development is a stack, not a model

Frontier AI at the substrate. Validated methods on top. AI in clinical development isn’t one thing. We wrote about why.

Get the whitepaper

RWD ages. Populations narrow. The result is the same: patient-level data alone can’t characterize expected outcomes for the trials you’re designing today.

The amendment is the symptom. Read about the cause.

An amendment is more than just a budget line. It’s part of Decision Debt: when every choice that left its context behind comes due later.